*originally published January 26, 2023

Medexus Pharmaceuticals (MDP.T) is a Canadian specialty pharma company on a mission to help humanity by bringing previously approved orphan drugs in other jurisdictions to the Canadian and American market.

Its robust portfolio of leading-edge therapeutics continues to grow market share, helping patients across North America improve quality of life. Trading at a fraction of its revenue, the company presents a unique opportunity for investors.

Jody Vance speaks with Ken d’Entremont, CEO and director of Medexus, to get a closer look at the company, its leadership, and what lays ahead for both investors and the medical community.

Enjoy!